CN Patent

CN113527294A — Mrtx849化合物的晶型及其制备方法和用途

Assigned to Du Chuang Shanghai Pharmaceutical Development Co ltd · Expires 2021-10-22 · 5y expired

What this patent protects

本发明涉及MRTX849化合物（化合物I）的晶型、制备方法、含有该晶型的药物组合物以及该晶型在制备治疗KRAS G12C基因突变引起的相关疾病药物中的用途。本发明提供的化合物I的晶型，对未来该药物的开发具有重要价值。

USPTO Abstract

本发明涉及MRTX849化合物（化合物I）的晶型、制备方法、含有该晶型的药物组合物以及该晶型在制备治疗KRAS G12C基因突变引起的相关疾病药物中的用途。本发明提供的化合物I的晶型，对未来该药物的开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN113527294A
Jurisdiction
CN
Classification
—
Expires
2021-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Du Chuang Shanghai Pharmaceutical Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.